Novo Nordisk A/S (NYSE:NVO) was among the stocks Jim Cramer covered on Mad Money as he discussed the wave of IPOs being the ...

By Chris Prentice and Mariam Sunny April 29 (Reuters) - Eli Lilly investors will be searching for something they won't find ...

Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Eli Lilly said on Monday ​it would buy ​privately ​held blood cancer treatment developer Ajax Therapeutics for up to $2.3 ...

Eli Lilly (LLY 2.56%) has established itself as the leader in the weight-loss drug market. Since this area is projected to ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S.

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio.

Eli Lilly has more to offer than some investors realize.

Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo. Read ...

Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...